Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Predictors of Treatment Response in Schizophrenia
NCT03730857Phase 1Completed
- Sponsor
- Calo Psychiatric Center
- Start
- Jan 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial in schizophrenia comparing Olanzapine Arm, Risperidone Arm and Paliperidone Arm (3 arms). Primary endpoint: Positive and Negative Syndrome Scale at 12 weeks. Started Jan 2008; status: completed.
02
Drugs
olanzapinerisperidonepaliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03730857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730857.